AG
UTHR icon

Ascent Group’s United Therapeutics UTHR Stock Holding History

Ascent Group’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$661K Sell
1,220
-36
-3% -$20.3K 0.02% 471
2026
Q1 		$745K Sell
1,256
-96
-7% -$47.8K 0.03% 423
2025
Q4 		$659K Buy
1,352
+8
+0.6% +$3.73K 0.02% 440
2025
Q3 		$563K Buy
1,344
+470
+54% +$158K 0.02% 474
2025
Q2 		$251K Buy
874
+156
+22% +$46.6K 0.01% 626
2025
Q1 		$221K Buy
718
+51
+8% +$17.5K 0.01% 638
2024
Q4 		$235K Sell
667
-73
-10% -$26.8K 0.02% 485
2024
Q3 		$265K Buy
+740
New +$250K 0.02% 464
2023
Q2 		– Sell
-947
Closed -$212K – 499
2023
Q1 		$212K Sell
947
-44
-4% -$10.8K 0.02% 454
2022
Q4 		$276K Sell
991
-203
-17% -$51.2K 0.03% 406
2022
Q3 		$275K Sell
1,194
-482
-29% -$108K 0.03% 396
2022
Q2 		$387K Sell
1,676
-506
-23% -$103K 0.05% 349
2022
Q1 		$391K Sell
2,182
-6,009
-73% -$1.14M 0.05% 356
2021
Q4 		$1.64M Buy
+8,191
New +$1.61M 0.21% 174

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Ascent Group's UTHR Position: Q2 2026 in Review

Ascent Group reduced its United Therapeutics (UTHR) stake by 2.9% in Q2 2026, selling an estimated $20.3K and leaving 1,220 shares worth $661K. The position accounts for 0.02% of the portfolio, ranked #471.

Ascent Group first reported a position in UTHR in Q4 2021 and has held it in 14 quarters since. The position peaked at $1.64M in Q4 2021. 875 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Ascent Group held 1,220 shares of United Therapeutics worth $661K as of Q2 2026.
  • Ascent Group sold 36 United Therapeutics shares in Q2 2026, an estimated $20.3K.
  • United Therapeutics made up 0.02% of Ascent Group's portfolio in Q2 2026, its #471 holding.
  • Ascent Group first reported a position in United Therapeutics in Q4 2021 and has held it in 14 quarters since.
  • Ascent Group's United Therapeutics position peaked at $1.64M in Q4 2021.
  • 875 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Ascent Group's 13F filing for Q2 2026, filed 3 Aug 2026.